Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$14.32 - $19.88 $2,792 - $3,876
-195 Reduced 1.03%
18,737 $277,000
Q1 2022

May 16, 2022

SELL
$15.39 - $20.25 $84,460 - $111,132
-5,488 Reduced 22.47%
18,932 $366,000
Q4 2021

Feb 09, 2022

BUY
$15.91 - $18.72 $5,043 - $5,934
317 Added 1.32%
24,420 $421,000
Q3 2021

Nov 15, 2021

SELL
$13.06 - $17.24 $54,355 - $71,752
-4,162 Reduced 14.72%
24,103 $403,000
Q1 2021

May 07, 2021

BUY
$11.06 - $12.87 $56,162 - $65,353
5,078 Added 21.9%
28,265 $338,000
Q4 2020

Feb 03, 2021

SELL
$9.33 - $12.48 $4,403 - $5,890
-472 Reduced 2.0%
23,187 $287,000
Q3 2020

Nov 04, 2020

BUY
$10.33 - $14.49 $33,086 - $46,411
3,203 Added 15.66%
23,659 $247,000
Q2 2020

Aug 05, 2020

SELL
$11.49 - $15.26 $26,128 - $34,701
-2,274 Reduced 10.0%
20,456 $286,000
Q1 2020

May 06, 2020

BUY
$8.11 - $15.23 $184,340 - $346,177
22,730 New
22,730 $267,000
Q3 2019

Nov 04, 2019

SELL
$10.05 - $14.55 $269,380 - $389,998
-26,804 Closed
0 $0
Q2 2019

Aug 07, 2019

SELL
$13.1 - $14.95 $18,523 - $21,139
-1,414 Reduced 5.01%
26,804 $390,000
Q1 2019

May 01, 2019

BUY
$13.69 - $20.06 $386,304 - $566,053
28,218 New
28,218 $396,000
Q3 2018

Oct 25, 2018

SELL
$13.63 - $15.7 $402,507 - $463,636
-29,531 Closed
0 $0
Q2 2018

Aug 02, 2018

SELL
$13.44 - $17.59 $59,377 - $77,712
-4,418 Reduced 13.01%
29,531 $408,000
Q2 2018

Jul 25, 2018

BUY
$13.44 - $17.59 $40,723 - $53,297
3,030 Added 9.8%
33,949 $482,000
Q1 2018

May 01, 2018

SELL
$13.8 - $16.99 $41,814 - $51,479
-3,030 Reduced 8.93%
30,919 $515,000
Q4 2017

Feb 05, 2018

BUY
$11.73 - $14.75 $11 - $14
1 Added 0.0%
33,949 $482,000
Q3 2017

Nov 03, 2017

BUY
$12.06 - $14.12 $409,412 - $479,345
33,948
33,948 $479,000

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.21B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.